金刚烷胺用于治疗GCH1基因突变复合杂合子中左旋多巴诱导的舞蹈症性运动障碍。
Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
作者信息
Furukawa Yoshiaki, Filiano James J, Kish Stephen J
机构信息
Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division, Toronto, Ontario, Canada.
出版信息
Mov Disord. 2004 Oct;19(10):1256-8. doi: 10.1002/mds.20194.
Amantadine suppressed severe levodopa-induced choreic dyskinesia, which developed at initiation of levodopa therapy, in two siblings manifesting dystonia with motor delay phenotype of GTP cyclohydrolase I deficiency caused by compound heterozygous GCH1 mutations. Our finding suggests a beneficial effect of amantadine on this type of dyskinesia frequently observed in relatively severe dopamine-deficient metabolic disorders.
金刚烷胺抑制了严重的左旋多巴诱发的舞蹈症性运动障碍，这种运动障碍在左旋多巴治疗开始时出现，在两名患有由复合杂合子GCH1突变引起的伴有运动迟缓表型的肌张力障碍的同胞中出现。我们的发现表明金刚烷胺对这种在相对严重的多巴胺缺乏性代谢疾病中经常观察到的运动障碍类型具有有益作用。
Zotero 插件